Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia

22Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

Abstract

Background: Hydromethylthionine is a potent inhibitor of pathological aggregation of tau and TDP-43 proteins. Objective: To compare hydromethylthionine treatment effects at two doses and to determine how drug exposure is related to treatment response in bvFTD. Methods: We undertook a 52-week Phase III study in 220 bvFTD patients randomized to compare hydromethylthionine at 200mg/day and 8mg/day (intended as a control). The principal outcomes were change on the Addenbrookes Cognitive Examination-Revised (ACE-R), the Functional Activities Questionnaire (FAQ), and whole brain volume. Secondary outcomes included Modified Clinical Global Impression of Change (Modified-CGIC). A population pharmacokinetic exposure-response analysis was undertaken in 175 of the patients with available blood samples and outcome data using a discriminatory plasma assay for the parent drug. Results: There were no significant differences between the two doses as randomized. There were steep concentration-response relationships for plasma levels in the range 0.3-0.6ng/ml at the 8mg/day dose on clinical and MRI outcomes. There were significant exposure-dependent differences at 8mg/day for FAQ, Modified-CGIC, and whole brain atrophy comparing patients with plasma levels greater than 0.346ng/ml with having minimal drug exposure. The exposure-response is biphasic with worse outcomes at the high concentrations produced by 200mg/day. Conclusions: Hydromethylthionine has a similar concentration-response profile for effects on clinical decline and brain atrophy at the 8mg/day dose in bvFTD as recently reported in AD. Treatment responses in bvFTD are predicted to be maximal at doses in the range 20-60mg/day. A confirmatory placebo-controlled trial is now planned.

References Powered by Scopus

Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria

4656Citations
N/AReaders
Get full text

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

3978Citations
N/AReaders
Get full text

Measurement of functional activities in older adults in the community

2195Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Tauopathies: new perspectives and challenges

143Citations
N/AReaders
Get full text

Tau oligomers neurotoxicity

83Citations
N/AReaders
Get full text

Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy

64Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Shiells, H., Schelter, B. O., Bentham, P., Baddeley, T. C., Rubino, C. M., Ganesan, H., … Wischik, C. M. (2020). Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer’s Disease, 75(2), 501–519. https://doi.org/10.3233/JAD-191173

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

52%

Researcher 5

24%

Lecturer / Post doc 3

14%

Professor / Associate Prof. 2

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 10

45%

Neuroscience 5

23%

Nursing and Health Professions 4

18%

Psychology 3

14%

Article Metrics

Tooltip
Mentions
News Mentions: 24

Save time finding and organizing research with Mendeley

Sign up for free